Strategy+ Advises Pfizer (NYSE: PFE) on Merger with Allergan (NYSE: AGN)

By

Strategy+ originated and advised on the largest pharma transaction in history; the $160 Billion merger of Pfizer (NYSE: PFE) and Allergan (NYSE: AGN).

Strategy+ advised one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the merger with global pharmaceutical company Allergan plc (NYSE:AGN). The definitive merger agreement was announced November 23, 2015. Pfizer and Allergan were combining in a stock transaction for a total enterprise value of approximately $160 billion.

Slated to be the largest pharma transaction in history, the agreement was later shut down by the Obama administration.

‍

Read the transaction press release

Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

strategyadd.com (the “Strategy Group LLC Website”) is a website operated by Strategy Group LLC, a privately held Florida limited liability company. Strategy Group LLC is not a registered broker-dealer. Strategy Group LLC provides strategic advisory and consulting services strictly in connection with mergers and acquisitions and capital raising. Strategy Group LLC does not act as a broker-dealer, does not engage in securities transactions, and does not receive transaction-based compensation. Strategy Group LLC’s services are limited to strategic advisory, and it does not perform or facilitate securities sales or trades.